Rockwell Medical, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

Rockwell Medical (Nasdaq: RMTI) announced participation in the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021. The company's executive management team will present virtually, and the presentation will be available on-demand starting September 13 at 7:00 a.m. ET on their website. Additionally, management will engage in one-on-one meetings with registered investors. Rockwell Medical is focused on innovative treatments for iron deficiency and has two FDA-approved therapies for hemodialysis patients.

WIXOM, Mich., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that members of its executive management team are scheduled to present at the H.C. Wainwright 23^rd Annual Global Investment Conference, being held virtually September 13-15, 2021.

The presentation will become publicly available for on-demand listening beginning on Monday, September 13 at 7:00 a.m. Eastern Time in the “Investors” section of the Company’s website at www.rockwellmed.com. A replay of the webcast will be archived on the Company’s website for 30 days.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.

About Rockwell Medical

Rockwell Medical is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron technology platform, Ferric Pyrophosphate Citrate (FPC), which has the potential to lead transformative treatments for iron deficiency in multiple disease states, reduce healthcare costs and improve patients’ lives. The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis, which are the first two products developed from the FPC platform. The Company is developing FPC for the treatment of iron deficiency in patients outside of dialysis, who are receiving intravenous medications in the home infusion setting, a large and rapidly growing segment of healthcare, and where these patients suffer from chronic diseases associated with high incidence of iron deficiency and anemia. In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States. For more information, visit www.rockwellmed.com.

CONTACTS

Investors:
Argot Partners
212.600.1902
Rockwell@argotpartners.com

Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com 

FAQ

When will Rockwell Medical present at the H.C. Wainwright Conference?

Rockwell Medical will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.

How can I access Rockwell Medical's presentation at the conference?

The presentation will be available for on-demand listening on Rockwell Medical's website starting September 13 at 7:00 a.m. ET.

What is the focus of Rockwell Medical's business?

Rockwell Medical specializes in developing treatments for iron deficiency and anemia management, particularly for patients undergoing hemodialysis.

What are Rockwell Medical's FDA-approved therapies?

Rockwell Medical has two FDA-approved therapies developed from its Ferric Pyrophosphate Citrate platform for patients undergoing hemodialysis.

How will Rockwell Medical engage with investors during the conference?

Management will participate in virtual one-on-one meetings with qualified investors registered for the conference.